STAT+: Pharmalittle: Power for Medicare to negotiate drug prices grows less likely; FDA OKs mix-and-match Covid booster shots
Top of the morning to you. And a fine one it is. Crystal clear blue skies and deliciously cool breezes are greeting us today, which calls for a celebration with — you guessed it — a cup of stimulation. Our flavor of choice today is maple bourbon, for those keeping track. Despite the gorgeous weather, there is much to keep us in front of the laptop. This sounds familiar, yes? So time to get started with a few tidbits. Have a wonderful day, and drop us a line if you hear anything interesting …
Senior Democrats insist they have not given up the push to grant Medicare broad powers to negotiate lower drug prices, The New York Times writes. They know that the loss of the provision, promoted by President Biden on the campaign trail and in the White House, could be the single most embarrassing defeat in the package, since it has been central to Democratic congressional campaigns for nearly three decades. But with at least three House Democrats opposing the toughest version of the measure, and at least one Senate Democrat against it, government negotiating power appears almost certain to be curtailed, if not jettisoned.
Continue to STAT+ to read the full story…
